CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Clinical safety rating: safe
No significant drug interactions at recommended doses May cause somnolence although less than first-generation antihistamines.
Cetirizine is a selective histamine H1-receptor antagonist. It inhibits the H1 receptor, reducing histamine-mediated effects such as edema, flare, and pruritus.
| Metabolism | Cetirizine undergoes minimal hepatic metabolism (<30%) to an inactive metabolite; the major route is renal excretion (approximately 70% as unchanged drug). |
| Excretion | Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% is eliminated in feces. |
| Half-life | Terminal elimination half-life is approximately 8.3 hours in healthy adults; prolonged to ~20 hours in renal impairment (CrCl <30 mL/min). |
| Protein binding | 93% bound to albumin and other plasma proteins. |
| Volume of Distribution | 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: ~70% with interindividual variability; absorption unaffected by food. |
| Onset of Action | Oral: 2 hours for significant wheal and flare reduction; maximal effect at 4–6 hours. |
| Duration of Action | Antihistaminic effects persist for 24 hours, allowing once-daily dosing; full suppression of histamine-induced wheal and flare up to 24 hours. |
5 mg or 10 mg orally once daily; maximum 10 mg per day.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-49 mL/min: 5 mg orally once daily. GFR <30 mL/min or ESRD (hemodialysis): Contraindicated. |
| Liver impairment | Child-Pugh Class A/B: No dose adjustment. Child-Pugh Class C: 5 mg orally once daily. |
| Pediatric use | Children 2-5 years: 2.5 mg orally once daily; max 2.5 mg/day. Children 6-11 years: 5 mg or 10 mg orally once daily; max 10 mg/day. Children ≥12 years: Same as adult dosing. |
| Geriatric use | Initiate at 5 mg orally once daily; increase to 10 mg if needed and tolerated. Monitor for sedation or anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions at recommended doses May cause somnolence although less than first-generation antihistamines.
| FDA category | Animal |
| Breastfeeding | Cetirizine is excreted into human breast milk. The milk-to-plasma (M/P) ratio has not been well established but is estimated to be low (~0.35 based on limited data). Peak milk concentrations occur about 4-6 hours after maternal dosing. The daily infant dose through milk is approximately 0.6-1.2% of the maternal weight-adjusted dose, which is unlikely to cause adverse effects in infants. However, caution is advised, particularly in neonates and preterm infants, due to potential sedation or anticholinergic effects. Breastfeeding while taking cetirizine is generally considered acceptable if used at recommended doses. |
■ FDA Black Box Warning
None.
| Common Effects | urticaria |
| Serious Effects |
["Hypersensitivity to cetirizine or any of its components, or to hydroxyzine.","Severe renal impairment (CrCl <10 mL/min) or patients undergoing hemodialysis."]
| Precautions | ["Somnolence: May cause drowsiness; avoid driving or operating hazardous machinery.","Renal impairment: Dose adjustment required in patients with decreased renal function (CrCl 11–31 mL/min: 5 mg once daily).","Hepatic impairment: No dose adjustment needed for hepatic impairment alone, but caution in combined hepatic and renal impairment.","Anticholinergic effects: Use with caution in patients with predisposing factors for urinary retention."] |
| Food/Dietary | No significant food interactions; can be taken with or without food. Avoid alcohol as it may increase drowsiness. |
Loading safety data…
| Teratogenic Risk | Cetirizine is classified as Pregnancy Category B. Animal studies have not revealed evidence of teratogenicity or fetotoxicity. In humans, large prospective studies have not shown an increased risk of major congenital malformations when used during the first trimester. However, as with all medications, use during pregnancy should be limited to cases where the benefit clearly outweighs the risk. There is insufficient data regarding third-trimester exposure, though no specific adverse fetal effects have been reported. |
| Fetal Monitoring | No specific fetal monitoring is typically required for maternal cetirizine use. However, in pregnant women with severe allergic conditions, monitoring maternal disease control (e.g., urticaria severity) and general fetal well-being via routine prenatal care is recommended. If used in the third trimester, be aware of potential maternal sedation affecting labor or lactation, though this is not routinely monitored. |
| Fertility Effects | In preclinical studies, cetirizine did not impair fertility in rats at doses up to 20 times the human daily dose. In humans, there are no specific reports of fertility impairment. However, antihistamines in general may have anticholinergic effects that could theoretically affect fertility via alterations in cervical mucus or uterine contractility, but clinically relevant effects are unlikely at recommended doses. |
| Clinical Pearls | Cetirizine is a second-generation antihistamine with minimal anticholinergic effects. Onset of action is within 1 hour; duration is approximately 24 hours. For hives, it may be more effective than loratadine. Avoid in severe hepatic impairment; dose adjustment needed in renal impairment (CrCl <30 mL/min: 5 mg once daily). Can cause somnolence in some patients, especially at higher doses. |
| Patient Advice | Take once daily; may cause drowsiness in some individuals, so avoid driving until you know how it affects you. · Do not exceed recommended dose; maximum 10 mg per day. · If you have kidney or liver disease, consult your doctor before use. · Discontinue if allergic reaction occurs (e.g., rash, swelling, difficulty breathing). · Shake the bottle well before each use. |